Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non‐viral infection: A Japanese multicenter observational study

This study compared the efficacy and safety of atezolizumab and bevacizumab (Atez/Bev) in patients with viral and non‐viral infection in clinical settings.

[1]  M. Kudo,et al.  Does first‐line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinib , 2022, Cancer medicine.

[2]  Y. Imai,et al.  Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma , 2022, Hepatology research : the official journal of the Japan Society of Hepatology.

[3]  J. Cheon,et al.  Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study , 2022, Cancers.

[4]  Y. Hiasa,et al.  Neutrophil–lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysis , 2022, European journal of gastroenterology & hepatology.

[5]  M. Kudo,et al.  Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. , 2022, Journal of Clinical Oncology.

[6]  Y. Hiasa,et al.  Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis , 2022, Hepatology research : the official journal of the Japan Society of Hepatology.

[7]  M. Kudo,et al.  Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. , 2021, Journal of hepatology.

[8]  M. Kudo,et al.  Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC‐B stage patients classified as beyond up to seven criteria – Multicenter analysis , 2021, Hepatology research : the official journal of the Japan Society of Hepatology.

[9]  Y. Hirooka,et al.  Early Changes in Alpha-Fetoprotein Are a Useful Predictor of Efficacy of Atezolizumab plus Bevacizumab Treatment in Patients with Advanced Hepatocellular Carcinoma , 2021, Oncology.

[10]  A. Zhu,et al.  VP10-2021: Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial , 2021, Annals of Oncology.

[11]  T. Kawaguchi,et al.  First‐line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study , 2021, Cancer medicine.

[12]  T. Takayama,et al.  Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma , 2021, JGH open : an open access journal of gastroenterology and hepatology.

[13]  H. Seno,et al.  Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma , 2021, Current oncology.

[14]  M. Kurosaki,et al.  Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice , 2021, Investigational New Drugs.

[15]  K. Shirabe,et al.  Lenvatinib for Hepatocellular Carcinoma Patients with Nonviral Infection Who Were Unlikely to Respond to Immunotherapy: A Retrospective, Comparative Study , 2021, Oncology.

[16]  M. Imamura,et al.  Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice , 2021, Cancers.

[17]  M. Kudo,et al.  Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience , 2021, Cancer reports.

[18]  J. Llovet,et al.  Evidence-based management of HCC: Systematic review and meta-analysis of randomized controlled trials (2002-2020). , 2021, Gastroenterology.

[19]  M. Kurosaki,et al.  The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study , 2021, Cancers.

[20]  M. Kudo,et al.  Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study , 2021, Scientific Reports.

[21]  I. Amit,et al.  NASH limits anti-tumour surveillance in immunotherapy-treated HCC , 2021, Nature.

[22]  H. Lee,et al.  Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study , 2021, Liver Cancer.

[23]  M. Kudo.  Impact of Multi-Drug Sequential Therapy on Survival in Patients with Unresectable Hepatocellular Carcinoma , 2021, Liver Cancer.

[24]  S. Kakizaki,et al.  Lenvatinib for Hepatocellular Carcinoma: A Literature Review , 2021, Pharmaceuticals.

[25]  A. Zhu,et al.  Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  E. Ogawa,et al.  Association between steatohepatitis biomarkers and hepatocellular carcinoma after hepatitis C elimination , 2020, Alimentary pharmacology & therapeutics.

[27]  J. Marrero,et al.  Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference , 2020, Hepatology.

[28]  Yulei N. Wang,et al.  Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. , 2020, The New England journal of medicine.

[29]  P. Chow,et al.  IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. , 2020, Future oncology.

[30]  F. Tacke,et al.  Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs , 2020, Liver international : official journal of the International Association for the Study of the Liver.

[31]  M. Kudo,et al.  CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC) , 2019, Annals of Oncology.

[32]  M. Abecassis,et al.  AASLD guidelines for the treatment of hepatocellular carcinoma , 2018, Hepatology.

[33]  M. Kudo,et al.  Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function , 2017, Liver Cancer.

[34]  E. Herrmann,et al.  Ongoing liver inflammation in patients with chronic hepatitis C and sustained virological response , 2017, PloS one.

[35]  M. Honda,et al.  Post‐progression survival and progression‐free survival in patients with advanced hepatocellular carcinoma treated by sorafenib , 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

[36]  Jin-liang Wang,et al.  Efficacy and Safety of Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma: A Systematic Review of Phase II Trials , 2012, PloS one.

[37]  Y. Kanda,et al.  Investigation of the freely available easy-to-use software ‘EZR' for medical statistics , 2012, Bone Marrow Transplantation.

[38]  T. Saibara,et al.  Platelet count for predicting fibrosis in nonalcoholic fatty liver disease , 2011, Journal of Gastroenterology.

[39]  U. Forssén,et al.  Prevalence of thrombocytopenia among patients with chronic hepatitis C: a systematic review , 2011, Journal of viral hepatitis.